Table 1.

List of drugs used in the study (updated March 25, 2022)

No.	Classification	Generic name	Brand name	Provided bya	Application in pediatric patients
1	ALK inhibitor	Ceritinib	ZYKADIA tablets 150 mg	Novartis Pharma K.K.	–
2	BCR-ABL tyrosine kinase inhibitor	Imatinib	Glivec tablets 100 mg	Novartis Pharma K.K.	–
3	mTOR inhibitor	Everolimus	AFINITOR tablets 2.5/5 mg AFINITOR dispersible tablets 2/3 mg	Novartis Pharma K.K.	Available
4	BRAF inhibitor	Dabrafenib	Tafinlar capsules 50/75 mg	Novartis Pharma K.K.	–
5	MEK inhibitor	Trametinib	Mekinist tablets 0.5/2 mg	Novartis Pharma K.K.	–
6	VEGF inhibitor	Pazopanib	Votrient tablets 200 mg	Novartis Pharma K.K.	–
7b	BRAF inhibitor	Dabrafenib	Tafinlar capsules 50/75 mg	Novartis Pharma K.K.	–
	MEK inhibitor	Trametinib	Mekinist tablets　0.5/2 mg
8	BCR-ABL tyrosine kinase inhibitor	Nilotinib	Tasigna capsules 50/150/200 mg	Novartis Pharma K.K.	Available
9	JAK inhibitor	Ruxolitinib	JAKAVI tablets 5/10 mg	Novartis Pharma K.K.	–
10	ALK inhibitor	Alectinib	ALECENSA capsules 150 mg	CHUGAI Pharmaceutical Co., LTD	Available
11	Anti-HER2 monoclonal antibody	Trastuzumab	HERCEPTIN for intravenous infusion 150 mg	CHUGAI Pharmaceutical Co., LTD	–
12	Anti-PD-L1 monoclonal antibody	Atezolizumab	TECENTRIQ for intravenous infusion 1200 mg	CHUGAI Pharmaceutical Co., LTD	–
13	TRK inhibitor	Entrectinib	ROZLYTREK capsules 100/200 mg	CHUGAI Pharmaceutical Co., LTD	Available
14	Anti-PD-1 monoclonal antibody	Nivolumab	OPDIVO I.V. infusion 240 mg	ONO Pharmaceutical Co., LTD	–
15b	BRAF inhibitor	Encorafenib	BRAFTOVI capsules 50 mg	ONO Pharmaceutical Co., LTD	–
	MEK inhibitor	Binimetinib	MEKTOVI tablets 15 mg	ONO Pharmaceutical Co., LTD	–
16	ALK inhibitor	Crizotinib	XALKORI capsules 200/250 mg	Pfizer Japan Inc	–
17	BCR-ABL tyrosine kinase Inhibitor	Ponatinib	ICLUSIG tablets 15 mg	Otsuka Pharmaceutical Co., Ltd	–
18	Cyclin-dependent kinase 4/6 inhibitor	Abemaciclib	VERZENIO tablets 50/100/150 mg	Eli Lilly and Company	–

ALK anaplastic lymphoma kinase, BCR-ABL breakpoint cluster region-Abelson, mTOR mammalian target of rapamycin, BRAF v-raf murine sarcoma viral oncogene homolog B1, MEK mitogen-activated protein kinase kinase-extracellular signal-regulated kinase, VEGF vascular endothelial growth factor, JAK Janus kinase, HER2 human epidermal growth factor type 2, PD-1 programmed cell death protein 1, TRK tyrosine kinase receptor, PD-1 programmed cell death 1

^aAll drugs were provided free of charge by pharmaceutical companies

^b#7 and #15 are combination therapies